FDA de­lays col­orec­tal can­cer de­ci­sion for Am­gen's Lumakras, a set­back in race with Bris­tol My­ers

The FDA has pushed back its de­ci­sion dead­line to move Am­gen’s KRAS in­hibitor Lumakras in­to metasta­t­ic col­orec­tal can­cer to Jan­u­ary, the com­pa­ny told End­points News …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER